Disrupting the Kinase–Phosphatase Equilibrium: A Unified Mechanism for Drug-Induced Eryptosis

The advent of targeted cancer therapies has revolutionized oncology, yet the off-target effects of these agents on healthy cells remain a significant clinical challenge. Anemia is one of the most frequent and debilitating adverse effects associated with pharmacological kinase inhibitors, often attributed to bone marrow suppression. However, accumulating evidence over the past fifteen years has illuminated an alternative mechanism: the direct induction of eryptosis, the programmed suicidal death of erythrocytes. This review provides a comprehensive analysis of the current state of knowledge regarding the induction of eryptosis by pharmacological modulators of the phosphorylation balance. We first detail the molecular machinery of eryptosis, then systematically evaluate the diverse classes of kinase inhibitors, from first-generation tyrosine kinase inhibitors to novel selective agents, as well as the emerging class of phosphatase inhibitors, examining the evidence for their eryptotic potential and the proposed molecular mechanisms driving this effect. Importantly, the majority of the evidence discussed derives from in vitro studies using erythrocytes from healthy donors, and we explicitly distinguish between experimentally demonstrated eryptosis and its proposed contribution to clinical anemia. Finally, we synthesize the clinical implications, discussing the impact on patient management, the potential for using eryptotic biomarkers as predictive tools for drug-induced anemia, and the broader pathophysiological consequences of chronic, drug-accelerated erythrocyte clearance. By integrating current mechanistic insights with clinical observations, this review underscores the importance of considering the kinase–phosphatase equilibrium as a potential determinant of drug safety and erythrocyte survival, and highlights the need for clinical studies to quantify the contribution of eryptosis to drug-induced anemia.